Newsroom

LONDON--(BUSINESS WIRE)--  09 January 2026 YOUNG & CO.’S BREWERY, P.L.C. Transaction in own shares Young & Co.’s Brewery, P.L.C. (the “Company”) announces that on 08 January 2026, in accordance with the terms of its share buyback programme announced by the Company on 17 November 2025 (the “Share Buyback Programme”), it has purchased the following Non-voting ordinary shares of 12.5 pence each (“Non-voting Shares” and the “Purchased Shares”) in the Company through Peel Hunt LLP (“Peel Hun...

LONDON--(BUSINESS WIRE)--  ISIN Code. XS2395556082 Our Ref. MO0810 ISSUE NAME. Commonwealth Bank of Australia Issue of AUD 40,000,000 Floating Rate Notes due 8 October 2031 Series 6446 Tranche 1 MTN INTEREST PERIOD. 08/01/2026 TO 08/04/2026 VALUE DATE. 08/04/2026 INTEREST RATE. 4.415 PCT NUM OF DAYS. 90 DAY BASIS. ACTUAL/365 FIXED (A005) CURRENCY CODE. AUD TOTAL INTEREST AMT. AUD 435,452.05 POOL FACTOR. N/A...

LONDON--(BUSINESS WIRE)--  Pershing Square Holdings, Ltd. Announces Transactions in Own Shares - 8 January 2026 Pershing Square Holdings, Ltd. (LN:PSH) (LN:PSHD) (“PSH”) today announced that it has purchased, through PSH’s agent, Jefferies International Limited (“Jefferies”), the following number of PSH’s Public Shares of no par value (ISIN Code: GG00BPFJTF46) (the "Shares"): Total Buyback   Ticker/s: PSH (LSE); PSHD (LSE) Date of Purchase: 8 January 2026 Number of Public Shares Purchased: 17,9...

瑞士，伯恩--(BUSINESS WIRE)--(美國商業資訊)-- 頂級數位資產財富平台Nexo今天宣布旗下推出的「Zero-interest Credit」(ZiC) 現已加入「Nexo Credit Line」成為該公司的旗艦級借貸解決方案。ZiC讓比特幣和以太坊持有者在固定期限內以零利率獲得流動性，無需承擔提前強制清算的風險。 在這之前，Nexo透過私人和場外交易服務提供結構化零利率貸款，開放Nexo的私人管道使用；現在則透過「Zero-interest Credit」開放給更多對象。這項服務在2025年促成了逾1.4億美元的流動性。 投資者、交易商和企業皆可使用的普及解決方案 「Zero-interest Credit」專為希望獲得流動性、但又不必犧牲長期投資倉位的客戶而設計，像是：不希望出售比特幣和以太坊的持有者、需要把握納稅時機或是籌集高額資金的富裕投資者、尋求風險可控制的市場機會的活躍交易者，以及使用數位資產為營運或策略計畫融資的企業。 借貸者的安心選擇 ZiC具備加密貨幣信貸領域罕見的可預測性。客戶無需監控貸款價值比 (LTV) 或擔心市場驅動的清算，即可享有零利率的...

LONDON--(BUSINESS WIRE)--  ISIN Code. XS3049815395 Our Ref. MT0180 ISSUE NAME. Commonwealth Bank of Australia Issue of GBP 250,000,000.00 Floating Rate Notes due April 2026 series 6666 Tranche 1 MTN INTEREST PERIOD. 15/10/2025 TO 15/01/2026 VALUE DATE. 15/01/2026 INTEREST RATE. 4.24402 PCT NUM OF DAYS. 92 DAY BASIS. ACTUAL/365 FIXED (A005) CURRENCY CODE. GBP TOTAL INTEREST AMT. GBP 2,674,313.97 POOL FACTOR. N/A...

GENT, Belgien--(BUSINESS WIRE)--MRM Health NV, ein biopharmazeutisches Unternehmen mit Produkten in der klinischen Entwicklung, das Pionierarbeit im Bereich mikrobiombasierter Therapeutika in den Feldern Entzündungskrankheiten und Immunonkologie leistet, gab heute bekannt, dass die US-amerikanische Arzneimittelbehörde FDA (Food and Drug Administration) den Antrag auf Zulassung als neues Prüfpräparat (Investigational New Drug, IND) für sein Leitprogramm MH002 genehmigt hat. Damit kann die klinis...

GENT, België--(BUSINESS WIRE)--MRM Health NV, een biofarmaceutisch bedrijf in klinische fase dat pioniert in de ontwikkeling van op het microbioom gebaseerde biotherapeutica voor inflammatoire aandoeningen en immuun-oncologie, kondigt vandaag aan dat het van de U.S. Food and Drug Administration (FDA) goedkeuring heeft verkregen voor een Investigational New Drug-aanvraag (IND), de vereiste regulatoire toelating om klinische studies naar nieuwe geneesmiddelen op te starten, voor zijn hoofdprogram...

GHENT, Belgium--(BUSINESS WIRE)--MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step for...

GAND, Belgique--(BUSINESS WIRE)--MRM Health NV, société biopharmaceutique clinique pionnière dans le développement de biothérapies basées sur le microbiome pour les maladies inflammatoires et l’immuno-oncologie, annonce avoir obtenu l’autorisation de la Food and Drug Administration (FDA) des États-Unis pour son dossier ‘Investigational New Drug’ (IND) concernant son programme phare MH002. Cette autorisation permet le lancement de l’essai clinique de Phase 2b STARFISH-UC chez des patients attein...

马萨诸塞州剑桥--(BUSINESS WIRE)--(美国商业资讯)-- 生命科学交易领域AI原生尽职调查的先驱Prudentia Sciences今日宣布完成2000万美元A轮融资。本轮融资由McKesson Ventures领投，SignalFire参投。现有投资者包括Iaso Ventures、Virtue和GV。继2024年完成700万美元种子轮融资后，该公司的融资总额已达2700万美元。 Prudentia Sciences提供AI原生平台，助力制药公司、生物技术公司和金融机构以前所未有的速度和严谨度评估突破性药物。公司将复杂的临床信号转化为可执行的洞察，从而加快交易流程，并为业务拓展、投资和尽职调查团队的收购、许可或投资决策提供战略支持。 公司的“人机回圈”模式能够协调买方、卖方和中介机构之间的无缝合作，以确保为行业最关键的投资决策提供安全合规的基础设施。 McKesson Ventures总裁Dave Schulte表示：“Prudentia正在革新生命科学机构利用数据评估资产和主动管理风险的方式。他们的AI原生平台通过实时洞察、无缝集成和智能自动化，加速科学尽职调查，将...